All Stories

  1. Dual T cell receptor/chimeric antigen receptor engineered NK‐92 cells targeting the HPV16 E6 oncoprotein and the tumor‐associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells

    Article • Journal of Medical Virology, April 2024, Wiley

    Dr Angel Cid Arregui

  2. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7

    Article • Cancer Letters, July 2023, Elsevier

    Dr Angel Cid Arregui

  3. Association of Prevotella intermedia with oropharyngeal cancer: A patient-control study

    Article • Heliyon, March 2023, Elsevier

    Dr Angel Cid Arregui

  4. Caracterización transcriptómica de bacterias relacionadas con eubiosis y disbiosis en pacientes con y sin carcinoma escamocelular oral

    Article • Infectio, August 2022, Asociacion Colombiana de Infectologia - ACIN

    Dr Angel Cid Arregui

  5. Generation of CAR-T cells using lentiviral vectors

    Article • January 2022, Elsevier

    Dr Angel Cid Arregui

  6. CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34+ Cell Mobilization

    Article • Cells, December 2021, MDPI AG

    Dr Angel Cid Arregui

  7. CAR-T Cells in Brain Tumors and Autoimmune Diseases – from Basics to the Clinic

    Article • October 2021, Bentham Science Publishers

    Solmaz Sadeghi, Dr Angel Cid Arregui, Mansour Poorebrahim

  8. Frontiers in Clinical Drug Research - CNS and Neurological Disorders

    Article • October 2021, Bentham Science Publishers

    Dr Angel Cid Arregui

  9. Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals

    Article • EBioMedicine, October 2021, Elsevier

    Dr Angel Cid Arregui

  10. Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein

    Article • Journal of Innate Immunity, August 2021, Karger Publishers

    Dr Angel Cid Arregui

  11. Up‐regulation of KISS1 as a novel target of Let‐7i in melanoma serves as a potential suppressor of migration and proliferation in vitro

    Article • Journal of Cellular and Molecular Medicine, June 2021, Wiley

    Dr Angel Cid Arregui

  12. Heparanase 2 (Hpa2) attenuates tumor growth by inducing Sox2 expression

    Article • Matrix Biology, May 2021, Elsevier

    Dr Angel Cid Arregui

  13. Correction: TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential

    Article • Cancer Gene Therapy, March 2021, Springer Science + Business Media

    Dr Angel Cid Arregui

  14. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential

    Article • Cancer Gene Therapy, March 2021, Springer Science + Business Media

    Dr Angel Cid Arregui

  15. Counteracting CAR T cell dysfunction

    Article • Oncogene, January 2021, Springer Science + Business Media

    Dr Angel Cid Arregui

  16. Recent developments in immunotherapy of cancers caused by human papillomaviruses

    Article • Immunology, December 2020, Wiley

    Dr Angel Cid Arregui

  17. Cáncer escamocelular orofaríngeo: experiencias y avances en la Facultad de Odontología, Pontificia Universidad Javeriana, Colombia

    Article • Universitas Odontologica, October 2020, Editorial Pontificia Universidad Javeriana

    Dr Angel Cid Arregui

  18. Genetically modified immune cells targeting tumor antigens

    Article • Pharmacology & Therapeutics, October 2020, Elsevier

    Dr Angel Cid Arregui

  19. Activating NK- receptors, homing selectins and inhibitory Siglecs recognize EBOLA-GP and HPV-L1NK

    Article • July 2020, Cold Spring Harbor Laboratory Press

    Dr Angel Cid Arregui

  20. Oral Microbiota Associated with Oral and Gastroenteric Cancer

    Article • The Open Microbiology Journal, February 2020, Bentham Science Publishers

    Dr Angel Cid Arregui

  21. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects

    Article • Critical Reviews in Clinical Laboratory Sciences, July 2019, Taylor & Francis

    Solmaz Sadeghi, Dr Angel Cid Arregui

  22. Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

    Article • Frontiers in Oncology, February 2019, Frontiers

    Dr Angel Cid Arregui

  23. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses

    Article • OncoImmunology, September 2018, Taylor & Francis

    Dr Angel Cid Arregui

  24. Book Review: Manual of Childhood Infections

    Article • The Open Microbiology Journal, September 2016, Bentham Science Publishers

    Dr Angel Cid Arregui

  25. Perspectives in the treatment of pancreatic adenocarcinoma

    Article • World Journal of Gastroenterology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Angel Cid Arregui

  26. Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1

    Article • Journal of Biomedical Science, January 2013, Springer Science + Business Media

    Dr Luis F Jave-Suarez, Dr Angel Cid Arregui

  27. Editorial - ONCOGENIC HUMAN PAPILLOMAVIRUSES - High-Risk Human Papillomaviruses: Towards a Better Understanding of the Mechanisms of Viral Transformation, Latency and Immune-Escape

    Article • The Open Virology Journal, December 2012, Bentham Science Publishers

    Dr Angel Cid Arregui

  28. Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice

    Article • The Open Virology Journal, December 2012, Bentham Science Publishers

    Dr Angel Cid Arregui

  29. Highly Sensitive Detection and Genotyping of HPV by PCR Multiplex and Luminex Technology in a Cohort of Colombian Women with Abnormal Cytology

    Article • The Open Virology Journal, June 2011, Bentham Science Publishers

    Dr Angel Cid Arregui

  30. MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines

    Article • Cancer Cell International, January 2011, Springer Science + Business Media

    Dr Luis F Jave-Suarez, Dr Angel Cid Arregui

  31. Therapeutic Vaccines Against Human Papillomavirus and Cervical Cancer

    Article • The Open Virology Journal, October 2009, Bentham Science Publishers

    Dr Angel Cid Arregui

  32. Onkologie. Immuntherapie beim Zervixkarzinom: Stand der Dinge

    Article • Geburtshilfe und Frauenheilkunde, October 2009, Thieme Publishing Group

    Dr Angel Cid Arregui

  33. Prophylactic HPV Vaccines

    Article • The Open Vaccine Journal, September 2009, Bentham Science Publishers

    Dr Angel Cid Arregui

  34. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions

    Article • BMC Cancer, January 2008, Springer Science + Business Media

    Dr Luis F Jave-Suarez, Dr Angel Cid Arregui

  35. Human Papillomavirus E7 Requires the Protease Calpain to Degrade the Retinoblastoma Protein

    Article • Journal of Biological Chemistry, December 2007, Elsevier

    Dr Angel Cid Arregui

  36. Heparin (GAG-hed) inhibits LCR activity of Human Papillomavirus type 18 by decreasing AP1 binding

    Article • BMC Cancer, August 2006, Springer Science + Business Media

    Dr Angel Cid Arregui

  37. Low-Dose Adenovirus Vaccine Encoding Chimeric Hepatitis B Virus Surface Antigen-Human Papillomavirus Type 16 E7 Proteins Induces Enhanced E7-Specific Antibody and Cytotoxic T-Cell Responses

    Article • Journal of Virology, October 2005, ASM Journals

    Dr Angel Cid Arregui

  38. A Synthetic E7 Gene of Human Papillomavirus Type 16 That Yields Enhanced Expression of the Protein in Mammalian Cells and Is Useful for DNA Immunization Studies

    Article • Journal of Virology, April 2003, ASM Journals

    Dr Angel Cid Arregui

  39. In Vivo Tissue-Specific Regulation of the Human Papillomavirus Type 18 Early Promoter by Estrogen, Progesterone, and Their Antagonists

    Article • Virology, March 2002, Elsevier

    Dr Angel Cid Arregui

  40. Intracellular routing of human amyloid protein precursor: Axonal delivery followed by transport to the dendrites

    Article • Journal of Neuroscience Research, May 1995, Wiley

    Dr Angel Cid Arregui

  41. Mechanisms of neuronal polarity

    Article • Neurobiology of Aging, May 1995, Elsevier

    Dr Angel Cid Arregui

  42. Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors.

    Article • Molecular and Cellular Biology, December 1994, ASM Journals

    Dr Angel Cid Arregui

  43. Adeno-associated virus type 2 interferes with early development of mouse embryos

    Article • Journal of General Virology, October 1994, Society for General Microbiology

    Dr Angel Cid Arregui